Psychedelic medicine,
here and now
A growing network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine
What we do
Empowering healing
Clinical care
Ketamine-assisted psychotherapy + other innovative therapies
Clinical research
Psychedelic clinical trials and protocol development
Therapeutic retreats
Legal, medically supervised psychedelic experiences
Our network
A global network dedicated to psychedelic medicine
Providing access to innovative, evidence based mental healthcare
Patients are referred to trusted partners for treatments not yet available in the US
Only active in jurisdictions with established regulations for the use of psychedelics
Our approach
Helping people, right now
Novamind enables safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
We provide ketamine-assisted psychotherapy and other novel treatments through our network of Cedar Psychiatry clinics and operate Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.
Through our retreat partners, we offer additional access to psychedelics in jurisdictions with established regulations for the use of these alternative medicines.
Our healthcare divisions
Our retreat partners
Our retreat partners
Press releases
March 22, 2021
Novamind to Present at Benzinga Biotech Conference
March 18, 2021
Novamind Partners with Merck for New Treatment-Resistant Depression Trial
March 03, 2021
Novamind Expands Leadership Team, Accelerating M&A
March 01, 2021
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
Why psychedelics?
“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology or the telescope is for astronomy.”
— Stanislav Grof, MD